natgillin/translations-raw huggingface dataset:
Pharmaceutical composition comprising the adult stem cells obtained according to the method as defined in any claim from 1 to 8 at a concentration comprised between 4-40x106 cells/ml, preferentially 7x106 cells/ml, as active principle together with pharmacologically acceptable adjuvants and/or excipients, said composition being formulated for local application, for use in the treatment of lesions chosen from the group consisting of cutaneous lesions, lesions to the tendons, to the ligaments, to the bones, to the mucous membranes in mammals, or fractures, of neurological or neurodegenerative pathologies chosen from the group consisting of Cushing's disease, head shaking, Wobbler's syndrome, breathing difficulties, paresis of the limbs in mammals, of acute or chronic inflammatory pathologies chosen from laminitis, periostitis, gastritis, arthrosis, inflammations caused by viral, bacterial, parasite, mycotic agents in mammals, of the syndrome of dilatation-torsion of the stomach in mammals. 
Farmaceutski pripravak koji sadrži odrasle matične stanice dobivene prema metodi kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8 u koncentraciji sadržanoj između 4-40x10"* stanica/mL, preporučeno 7x10* stanica/mL, kao aktivnu tvar, zajedno sa farmakološki prihvatljivim adjuvansima i/ili ekscipijensima, pri čemu se spomenuti pripravak formulira za lokalnu primjenu, za uporabu u liječenju lezija izabranih iz skupine koja sadrži kožne lezije, lezije tetiva, ligamenata, kostiju, mukozne membrane u sisavcima, ili fraktura, neuroloških ili neurodegenerativnih patologija izabranih iz skupine koja se sastoji od Cushingove bolesti, trešnje glave, Wobblerovog sindroma, teškoća s disanjem, pareze udova u sisavcima, akutnih i kroničnih upalnih patologija izabranih iz laminitisa, periostitisa, gastritisa, artroze, upala uzrokovanih virusnim, bakterijskim, parazitskim, mikotskim agensima u sisavcima, sindroma dilatacije-torzije želuca u sisavcima,
The process of claim 18, wherein the suitable Boc deprotecting agent is HCl or trifluoroacetic acid (TFA) and the suitable solvent is acetone or dichloromethane (DCM). 
Postupak u skladu s patentnim zahtjevom 19, naznačen time, da je prikladno sredstvo za uklanjanje zaštite Boc HCI ili TFA, a pogodno otapalo je aceton ili CH,Cb.
The present composition is advantageously provided in a relatively concentrated form, e.g. with a solids content of at least 10 wt. %. 
Sadašnji pripravak je korisno pružen u relativno koncentriranom obliku, npr. se sadržajem čvrste tvari od najmanje 10 mas.%.
A composition for use in a method for treating a hematological malignancy, wherein said method comprises administering imetelstat or imetelstat sodium to a human identified as having a hematological malignancy with the presence of 
Pripravak koji sadrži imetelstat ili natrijev imetelstat za uporabu za liječenje hematološke malignosti kod sisavaca koji je identificiran da ima hematološku malignost uz prisutnost genotipa mutacije spliceosoma, prstenastih sideroblasta unutar koštane srži, ili oboje pod uvjetima pri kojim se liječi navedena hematološka malignost.
M1 receptors are found primarily in brain and other tissue of the central nervous system, M2 receptors are found in heart and other cardiovascular tissue, and M3 receptors are found in smooth muscle and glandular tissues. 
M1 receptori se prvenstveno nalaze u mozgu i drugom tkivu centralnog živčanog sustava, M2 receptori se nalaze u srcu i drugom tkivu centralnog živčanog sustava, a M3 receptori se nalaze u glatkom mišićnom i žljezdanom tkivu.
A compound of formula (II): wherein 
Spoj u skladu s patentnim zahtjevom 1 koji ima formulu (II):
A compound having Formula (IVa-2): or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein: 
NZ >N o (IVa-2) ili njegova farmaceutski prihvatljiva sol, solvat, tautomer, stereoizomer, ili deuterirani analog, naznačen time da:
Tramadol hydrochloride and polyethylene oxide powder were mixed in a free-fall mixer. 
Tramadolhidroklorid i prah polietilenoksida su smiješani u gravitacionoj miješalici.
A molecule comprising a saccharide moiety of formula: 
Molekula koja sadrži saharidni ostatak formule:
In some embodiments, the anti-obesity agents are selected from the group consisting of orlistat, sibutramine, bromocriptine, ephedrine, leptin, and pseudoephedrine. 
U nekim oblicima, sredstva protiv debljine su izabrana iz skupine koju čine orlistat, sibutramin, bomokriptin, efedrin, leptin i pseudoefedrin.
R is a moiety comprising at least one functional group selected from the group consisting of a double bond, halo, cyano, hydroxyl, sulfonyl, aldehyde, carbonyl, carboxyl, ether, ester, carboxamide, amine, hydrazinyl, ammonium, azide and 5- or 6-membered heterocyclic group with the proviso that R is not allyl; 
R je vrsta koja obuhvaća barem jednu funkcionalnu skupinu izabranu iz grupe koja obuhvaća halo, cijano, hidroksil, sulfonil, aldehid, karbonil, karboksil, eter, ester, karboksamid, amin, hidrazinil, amonij, azid i 5- ili 6-eročlanu heterocikličku skupinu;
Method according to claim 1, characterized in, that pozzolan is subjected to a pre-classification to separate a fraction with a retention on the sieve 45 microns which is at least 99% and in that the oversized particles are grinded to a fineness with a retention on the sieve 30 microns which is less than 5%. 
Postupak prema patentnom zahtjevu 1, naznačen time što se pucolan podvrgava pred-klasifikaciji kako bi se odvojila frakcija s retencijom na situ od 45 mikrona koja je najmanje 99 % i time što se prevelike čestice usitnjavaju do finoće s retencijom na situ od 30 mikrona koja je manja od 5 %.
The method of claim 14, wherein the step of cooling the sheet is performed at a cooling rate of from 200 °C per second to 600 °C per second or wherein the step of cooling the sheet is performed at a cooling rate of from 2000 °C per second to 3000 °C per second. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što se korak hlađenja lima provodi pri brzini hlađenja od 200 °C u sekundi do 600 °C u sekundi ili što se korak hlađenja lima provodi pri brzini hlađenja od 2000 °C u sekundi do 3000 °C u sekundi.
hetCyc3 and hetCyc3a are independently a 6-membered heterocyclic ring having 1-2 ring N atoms and optionally substituted with a halogen; 
hetCyc3 i hetCyc3a su neovisno 6-eročlani heterociklički prsteni s 1-2 N atoma u prstenu i izborno su supstituirani s halogenom;
Ulipristal acetate, or any metabolite thereof, for use in treating or preventing a tumour derived from leiomyomata according to anyone of claims 1 to 8 wherein it is to be administered with a daily dosage of 5 to 20 mg, preferably from 5 to 15 mg. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema bilo kojem od zahtjeva 1-3 pri čemu se primjenjuje u dnevnoj dozi od 5 do 15 mg.
The composition according to claim 5, wherein the anti-HCV agent is an inhibitor of HCV NS3 protease. 
Sastav prema zahtjevu 15, naznačen time, da sljedeće anti-HCV-sredstvo je inhibitor HCV NS3-proteaze.
Exemplary medical conditions, diseases, and disorders include anxiety, pain, sleep disorders, eating disorders, inflammation, multiple sclerosis and other movement disorders, HIV wasting syndrome, closed head injury, stroke, Alzheimer's disease, epilepsy, Tourette's syndrome, epilepsy, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, symptoms of drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, or cerebral vasospasm. 
HIV-a, unutrašnja ozljeda glave, moždani udar, Alzheimerova bolest, epilepsija, Touretteov sindrom, Niemann- Pickova bolest, Parkinsonova bolest, Huntingtonova koreja, optički neuritis, autoimuni uveitis, simptomi odvikavanja od narkotika, mučnina, povraćanje, seksualna disfunkcija, post traumatski stresni poremećaj, cerebralni vazospazam, glaukom, sindrom iritabilnog crijeva, upalna bolest crijeva, imunosupresija, gastroezofagusna refluksna bolest, paralitički ileus, sekretorni proljev, čir na želucu, reumatoidni artritis, neželjena trudnoća, hipertenzija, karcinom, hepatitis, alergijska bolest dišnih putova, autoimuni dijabetes, kronični pruritis, te neuroupala.
Embodiment 206 A pharmaceutical composition comprising a peptide according to any of embodiments 1 to 176 or an immunoconjugate according to any of embodiments 202 to 205 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži protutijelo prema bilo kojem od zahtjeva 1 do 12, imunokonjugat prema zahtjevu 13, ili bispecifična ili multispecifična molekulu prema zahtjevu 14 i farmaceutski prihvatljivi nosač.
The method of one of claims 1 to 7, wherein the electrical circuit (19) is sunken with respect to the cartridge front face (33), so that electrical contact with the electrical connector circuit (18) of the cartridge receiving structure (4) is made after the other interfaces are connected. 
Uložak za tintu (3) u skladu s patentnim zahtjevom 12, naznačen time što električni krug (19) ulazi u prednju površinu uloška (33), tako da se električni kontakt uspostavi nakon povezivanja drugih sučelja.
The information system according to any of the preceding claims, wherein the exit surface of the optical element has a geometric shape which reduces within a desired angle range (15) the back reflection of the sun light (11). 
Optički element (OP) u skladu sa bilo kojim od prethodnih patentnih zahtjeva, pri čemu izlazna površina optičkog elementa ima geometrijski oblik koji smanjuje unutar željenog opsega kuta (15) pozadinsku refleksiju sunčeve svijetlosti (11).
Thus, it can be determined whether any given mutein has substantially the same activity as IL-18BP by means of routine experimentation comprising subjecting such a mutein, e.g., to a simple sandwich competition assay to determine whether or not it binds to an appropriately labeled IL-18, such as radioimmunoassay or ELISA assay. 
Tako, može se odrediti da li pojedini mutein posjeduje vrlo sličnu aktivnost kao i IL-18BP rutinskim eksperimentiranjem koje obuhvaća ispitivanje muteina, primjerice testom kompeticije HR P20070196 T3 jednostavnog sendviča kako bi se odredilo da li se ili ne vezuje na valjano označenog IL-18, a takve metode su radioimuno testovi ili ELISA test.
optionally instructions for use; 
izborno uputa o upotrebi;
Process of claims 1 or 2, wherein R1 is hydrogen or C1-4-alkyl and R2 is hydrogen or C1-4-alkyl; or R1 and R2 together with the nitrogen and the carbon atom to which they are attached form a pyrrolidine ring of proline which is optionally substituted with hydroxy or halogen; 
je vodik ili C1-4-alkil i je vodik ili C1-4-alkil; ili i R2 zajedno s dušikovim atomom i atomom ugljika, na koje su vezani, tvore pirolidinski prsten prolina, koji se opcijski supstituira s hidroksi skupinom ili halogenom;
and R2, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms, 
Y je -OH; i R2, koje mogu biti međusobno identične ili različite, mogu biti vodik, alkil-skupina koja ima od jednoga do pet atoma ugljika ili alkoksi-skupina koja ima od jednoga do tri atoma ugljika;
This fraction was pooled with the first part of the elution gradient (before 28% of ACN). 
Frakcija je bila sakupljena s pomoći prvoga dijela elucijskog gradijenta (prije 28% ACN-a).
cyclizing the above compound of formula IVb to obtain a compound of formula Vb in the form of diastereoisomeric mixture (R,S+S,S) 
IViR Eas) d de gdje je Y kako je gore definiran; cikliziranje navedenog spoja formule IVb, da bi se dobio spoj formule Vb u obliku dijasteroizomerne smjese (R, S+8, S) a pai
The antitumor drug and/or anticancer drug according to claim 23, which is for use against lung cancer, urothelial cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastrointestinal stromal tumor, uterine cervix cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulval cancer, thyroid cancer, penis cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, or sarcoma. 
Antitumorski lijek i/ili antikancerogeni lijek u skladu sa patentnim zahtjevom 12, za primjenu u liječenju raka pluća, urotelijalnog raka, kolorektalnog raka, raka prostate, raka jajnika, raka gušterače, raka dojke, raka mokraćnog mjehura, raka želuca, gastrointestinalnog stromalnog tumora, raka grlića materice, raka jednjaka, karcinoma pločastih stanica, peritonealnog raka, raka jetre, hepatocelularnog raka, raka debelog crijeva, raka rektuma, kolorektalnog raka, raka endometrija, raka materice, raka žlijezda slinovnica, raka bubrega, raka vulve, raka štitnjače, raka penisa, leukemije, malignog limfoma, plazmacitoma, mijeloma, ili sarkoma.
Evaporation to dryness gave a crystalline omeprazole litium salt, mp. 
Uparavanje do suhog dalo je kristlanu omeprazol litij sol t.t.
reacting the compound of Formula LXII with a compound of Formula IXa. 
-M Formula IXa čime se dobiva spoj Formule LXIII:
The pharmaceutical composition according to claim 1 or 2, wherein the composition provides steady state plasma levels of 3 a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 50 ng/mL to 250 ng/mL. 
Farmaceutski sastav za uporabu prema patentnom zahtjevu 1, naznačen time, da sastav daje stacionarno stanje razine u plazmi 3a-hidroksi-3f-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u području od 50 ng/ml do 250 ng/ml.
An article of manufacture comprising a packaging material which comprises a label for use in treating a condition selected from the group consisting of ischemia, a condition requiring connective tissue regeneration and a condition requiring connective tissue repair, said packaging material packaging a pharmaceutically effective amount of adherent placental or adipose cells. 
Proizvodni artikl koji sadrži ambalažni materijal na kojem je uputa, naznačen time što je namijenjen upotrebi u liječenju stanja koje se bira iz skupine koju čine ishemija, stanje kod kojeg je potrebno regeneriranje vezivnog tkiva i stanje kod kojeg je potreban popravak vezivnog tkiva, gdje je navedeni ambalažni materijal pakiranje za farmaceutski djelotvornu količinu adherentnih stanica posteljice ili masnih stanica.
The method of claim 1, wherein the immune response is an antigen-specific T cell response, such that an antigen-specific T cell response is stimulated. 
Antitijelo, antigen-vezujući dio, bispecifična molekula, ili imunokonjugat za primjenu u skladu sa patentnim zahtjevom 24, gdje imunološki odgovor je odgovor antigen-specifične T stanice, tako da je odgovor antigen-specifične T stanice stimuliran.
Ascorbic acid is used in the treatment and prevention of deficiency. 
Askorbinska kiselina se rabi u liječenju i prevenciji nedostatka.
US 4,962,179 reports a different approach using epoxide modified fatty acid in the form of epoxidised vegetable oils. 
US 4,962,179 opisuje drugačiji pristup upotrebom epoksidno modificirane masne kiseline u obliku epoksidiranih biljnih ulja.
A mixed turf (1) as claimed in one or more of claims 6-7, wherein said sandy material of said upper layer (7) consists of crushed stones and sand a fraction of which higher than 85% having particle sizes included between 0.05 mm and 2.00 mm. 
Mješoviti travnjak (1) prema jednom ili više zahtjeva 6-7, naznačen time da je navedeni pjeskoviti materijal u navedenom gornjem sloju (7) drobljeni kamen stlačenog granulometrijskog sastava između 0,05 1 2,00 mm za frakciju veću od 85%.
A process for producing a compound according to formula (18) or a salt thereof comprising the steps 
Postupak za proizvodnju spoja u skladu sa sljedećom formulom (18) ili njegove soli: e od "4 (
Additives, such as alkali aluminates and alkali salts, alkali silicates and alkali hydroxides, for example, which further increase the pH level of the solution and, in combination with this, the reactivity of C5S2$, are particularly preferred and can be metered in an amount ranging from 0.01 to 10% by weight, preferably 0.5 to 5% by weight and even more preferably 1 to 2% by weight. 
Vezivno sredstvo sukladno barem jednom zahtjevu 1 do 6, naznačeno time što vezivno sredstvo sadrži litijeve soli i hidrokside i/ili druge alkalijeve soli i hidrokside i alkalijeve silikate kao dodatke mješavini ili daljnje mješavine, s dodacima mješavini poput alkalijskih soli, silikata 1 hidroksida, koji povećavaju pH vrijednost otopine i posljedično reaktivnost C5S2$, osobito poželjnim.
a connection ring (18) connecting said second (14) and third (15) portions and which, in section, is arched and has a concavity facing downwards. 
- spojni prsten (18) koji povezuje navedeni drugi (14) i treći (15) dio 1 koji je u presjeku zaobljen, a konkavna strana okrenuta je prema dolje.
The salt according to embodiment 34, which salt is the DL-lactate salt of the compound of formula [I]. 
Sol u skladu s patentnim zahtjevom 1, naznačena time, što je to sol vodikovog malonata spoja formule [I].
As illustrated, the end containment sections (2, 4, 10, 12) of the greened sound-absorbing structure comprise frames (20) of progressively lower height compared with those of the central containment sections (6, 8). 
Konstrukcija u skladu s patentnim zahtjevom 1, naznačena time, da sredstva okvira sadrže više potpornih okvira (20), a potporni okviri krajnjih ograđenih sekcija (2, 4, 10, 12) su niže visine u usporedbi s onima od središnjih ograđenih sekcija (6, 8).
The process of claim 1, wherein the sulfonating agent is selected from chlorosulfonic acid or sulfur trioxide. 
Postupak prema zahtjevu 1, naznačen time što je sredstvo za sulfoniranje klorosulfonska kiselina ili sumporov trioksid.
According to another preferred embodiment, the process of the invention comprises, after the purification, concentrating the resulting unsaturated compounds at a temperature lower than the boiling point of the solvent and at a pressure lower than 200 mm Hg and then evaporating to dryness under vacuum or inert gas flow. 
Prema još jednom poželjnom ostvarenju, postupak iz izuma sadržava, nakon pročišćavanja, koncentriranje dobivenih nezasićenih spojeva pri temperaturi nižoj od vrelišta otapala 1 pri tlaku nižem od 200 mm Hg i zatim uparavanje do suhoće pod vakuumom ili protokom inertnog plina.
Thereupon there were prepared 96 parts by weight of an aqueous mixture containing 0.5% of sodium dodecylbenzene sulphonate (surfactant) and 1.6% of phosphoric acid (catalyst). 
Pripremimo 96 mas. dijelova vodene smjese, koja sadrži 0,5 % natrijevog dodecilbenzen sulfonata (površinski aktivna tvar) i 1,6 % fosforove kiseline (katalizator),
Evaluation of the efficacy of different alternative nucleophilic catalysts 
Datum objave europske prijave patenta:
The hydrocarbyl succinimide may include the reaction product of polyisobutylene of molecular weight from about 500 to about 3000 Daltons and maleic anhydride. 
Tekućina za obradu prema zahtjevu 4, naznačena time što nadalje sadrži hidrokarbil sukcinimid; pri čemu hidrokarbil sukcinimid sadrži reakcijski produkt poliizobutilena molekulske mase od 500 do 3000 Daltona 1 maleinski anhidrid.
The preparation method according to claim 12, characterized in that after the step 3) of preparation of a drug-loaded liposome, the said method also comprises the following step of: 
Postupak pripreme prema zahtjevu 10, naznačen time što nakon koraka 3) pripreme liposoma napunjenog lijekom, taj postupak također obuhvaća sljedeći korak:
The dose counter according to claim 1, wherein the second ratchet drive pawl is resiliently biased into contact with the gear teeth of the first gear wheel with which it is arranged for engagement, the second ratchet drive pawl being displaceable away from the first gear wheel against the bias. 
Brojač doza u skladu s patentnim zahtjevima 2 ili 3, pri čemu je drugi pogon zapornog zaklopca (132) elastično odmaknut u kontaktu sa zupcima zupčanika kotača sa zupčanikom s kojim je postavljen za pokretanje, zaklopac se može odmaknuti od kotača sa zupčanikom naspram odstupanju.
Preferably, the residue comprises at least about 5, 10, 20, 50, 100, 500, or 1000 moles of the boronic ester compound of formula (I). 
Postupak prema patentnom zahtjevu 17, pri čemu ostatak sadrži najmanje pet mola spoja estera organoborne kiseline formule (7).
Host cell expressing an antibody heavy chain and/or an antibody light chain, wherein said host cell comprises the nucleic acid of claim 13. 
Stanica domaćin koja eksprimira teški lanac antitijela i/ili laki lanac antitijela, pri čemu navedena stanica domaćin sadrži nukleinsku kiselinu prema patentnom zahtjevu 12.
The method of controlling phytopathogenic fungi of agricultural crops comprising applying an effective amount to said agricultural crops of a fungicidal composition according to claim 1 for the control of Plasmopara viticola on vines, Phytophtora infestans and Botrytis Cinerea on tomatoes, Puccinia recondita, Erisiphae graminis, Helminthosporium teres, Septoria nodorum and Fusarium spp. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva od 8 do 10, naznačena time što je namijenjena suzbijanju gljivica Plasmopara viticola kod vinove loze, Phytophtora infestans i Botrytis cinerea kod rajčica, Puccinia rekondita, Erysiphe graminis, Helminthosporium teres, Septoria nodorum i Fusarium spp.
As indicated at Figure 6C, a door 201 in housing 200 allows access to pump 40, compressor 50, and other components (e.g. solenoids, valves, tubing),. 
Kako je prikazano na slici 6C, vrata 201 na kućištu 200 omogućuju pristup pumpi 40, kompresoru 50, i drugim komponentama (na primjer solenoidima, ventilima, cjevovodima).
The feed according to any one of claims 1-3, characterized in that it contains the fatty acid mixture in an amount of 1-10% by weight. 
Krmna smjesa za preživače prema zahtjevu 1 ili 2, naznačena time što je ukupna količina mješavine masnih kiselina u hrani 10,1 – 50%.
The lipid compound according to claim 5, wherein X is a carboxylic acid derivative in the form of an ethyl ester. 
Lipidni spoj prema zahtjevu 11, pri čemu X je derivat karboksilne kiseline u obliku etil estera.
A pharmaceutical composition comprising the antibody of any one of claims 1 to 4 and a pharmaceutically acceptable carrier or excipient. 
Farmaceutska kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 2 1 farmaceutski prihvatljiv nosač ili ekscipijens.
Description of a preferred embodiment of the invention 
Datum podnošenja europske prijave patenta:
The method as recited in any one of claims 8 to 14, wherein the sewn ball is a sewn football or a sewn volleyball, or wherein the housing (4) comprises 6-32 leather pieces. 
Postupak prema bilo kojem od zahtjeva 6 do 10, naznačen time, da se kod zašivene lopte radi o zašivenoj lopti za nogomet ili za rukomet, ili time da se vanjski omotač (4) sastoji od 6 do 32 kožna komada.
An anti-FcRn antibody or FcRn-binding fragment thereof which binds to the same epitope of human FcRn as an anti-FcRn antibody or FcRn-binding fragment thereof comprising a heavy chain sequence given in SEQ ID NO: 25 and a light chain comprising the sequence given in SEQ ID NO: 16. 
Anti-FcRn antitijelo ili njegov fragment prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time, što je antitijelo ili njegov vezujući fragment Fab-dsFv koji sadrži teški lanac koji se sastoji od sekvence navedene u SEQ ID NO: 42 i laki lanac koji se sastoji od sekvence navedene u SEQ ID NO: 40.
A compound if formula (I) according to claims 1-3 having the structure 
Spoj ako formula (1) prema zahtjevima 1-3 ima strukturu
or a pharmaceutically acceptable salt thereof. A compound according to claim 1 selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine: